Search results
Results From The WOW.Com Content Network
Secukinumab was discovered and developed by Novartis using developmental name AIN457, and the first publication was a Phase I trial published in 2010. In January 2015, secukinumab was approved in the United States and in the European Union to treat adults with moderate-to-severe plaque psoriasis.
Hook's Drug Stores was an Indianapolis, Indiana-based drug store chain which was founded in 1900 by John A. Hook. The chain flourished throughout central Indiana for most of the 20th-century. Hook's did business under its own banner, the SupeRX Drug Stores banner outside its core market, and the Brooks Pharmacy banner after acquiring the New ...
Novartis. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
Scemblix was also tested against Novartis' Tasigna, Bristol Myers Squibb's Sprycel and Pfizer's Bosulif. It helped almost 30% more patients achieve MMR compared to Glivec at the end of 48 weeks.
(Reuters) -Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.
Novartis (NVS) gets a boost from strong performance of new drugs. Strategic acquisitions to foray into promising areas has also boosted investor sentiment.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Donate; Help; Learn to edit; Community portal; Recent changes; Upload file
(Reuters) -Voyager Therapeutics said on Tuesday Swiss-based drugmaker Novartis would pay $100 million upfront as part of a licensing deal to develop gene therapy candidates for genetic disorders.